Clinical trial · Interventional
Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
A Pilot Study to Evaluate the Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Eltrombopag may improve the cell collection available for Autologous Stem Cell Transplant(ASCT). The overall goal is to determine if adding Eltrombopag to the standard ASCT will increase the number of blood cells collected and reduce the number of times blood needs to be collected. This study will also determine the highest dose of Eltrombopag that can be used without causing serious side effects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Eltrombopag | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Eltrombopag
- description
- 0 mg Eltrombopag
- interventionNames
- Drug: Eltrombopag
Primary outcomes (3)
- measure
- Evaluate the median fold increase in the number of CD34+ cells/kg mobilized at each dose level.
- timeFrame
- 1 year
- description
- Evaluate the median fold increase in the number of CD34+ cells/kg mobilized at each dose level.
- measure
- Evaluate the number of apheresis procedures required to obtain at least 2 x 10^6 CD34+ cells/kg at each dose level
- timeFrame
- 1 year
- description
- Evaluate the number of apheresis procedures required to obtain at least 2 x 10\^6 CD34+ cells/kg at each dose level
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Multiple myeloma * Stable or responsive disease after at least 2 cycles of conventional chemotherapy * Slated to undergo autologous peripheral blood stem cell transplant * Normal organ and marrow function Exclusion Criteria: * Myocardial infarction within 6 months of treatment * Receiving other study agents * Pregnant or breastfeeding * Uncontrolled intercurrent illness * Evidence of active or recent history of thromboembolic disease * Previous history of primary platelet disorder or bleeding disorder * History of a different malignancy unless disease free for at least 5 years
References
Publications (0)
Data not yet available